Why Zevra Therapeutics, Inc.’s (ZVRA) Stock Is Up 6.61%
As of Monday, November 16, Zevra Therapeutics, Inc.’s ZVRA share price has surged by 6.61%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Jenna Brashear
Michael Rose
Rosalio Madrigal
| Share Statistics | ZVRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $539.7 | $403.8 | 40% |
|
| Shares Out (Mil) | 61.7 | 47.2 | 52% |
|
| Institutional Ownership | 98.4% | 82.0% | 78% |
|
| Float (Mil) | 54.0 | 49.0 | 48% |
|
| Beta | 0.99 | 0.68 | 59% |
|
| Avg Daily Volume (000s) | 1,289 | 347 | 73% |
|
| Price Change (52-week) |
(6.5%) | 51.1% | 47% |
|
| Growth | ZVRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 51.6% | 6.6% | 96% |
|
| Net Income (5yr) | 53.4% | (1.4%) | 95% |
|
| EPS (5yr) | 19.3% | 15.1% | 67 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 22.3% | (15.1%) | 81% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 2 | 4 | |
| Current EPS | $0.185 | $1.270 | $0.890 | |
| Month Ago EPS | $0.195 | $1.140 | $1.050 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $0.195 | $1.140 | $1.050 | |
| Year/Year Chg | (28.6%) | (5.9%) | 1.9% | |
| Financials | ZVRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $148 | $275 | 29% |
|
| Net Income (TTM) (Mil) | $78 | ($11) | 58% |
|
| EPS (TTM) | $1.285 | ($0.600) | 63% |
|
| Operating Cash Flow (TTM) (Mil) | $39 | ($7) | 44% |
|
| Net Cash Flow (TTM) (Mil) | $68 | $1 | 73% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | $470 | $373 | 34% |
|
| Valuation | ZVRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.26 | 2.20 | 61% |
|
| P/E | 7.4 | 21.1 | 11% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.4 | 1.1 | 20% |
|
| Ratios | ZVRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 95.4% | 69.4% | 95% |
|
| Net Margin | 52.8% | 3.5% | 97% |
|
| ROA | 26.7% | (24.6%) | 98% |
|
| ROE | 41.9% | (24.4%) | 92% |
|
| Liabilities to Assets | 23.8% | 32.0% | 16% |
|
| F-Score | 6 | 3 | 67% |
|
Passing Stock Screens
As of 11/19/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 7.0% |
| +/- S&P 500: | -0.4 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors